99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study
暂无分享,去创建一个
Fan Wang | Feng Wang | Zhaofei Liu | Jiyun Shi | Bing Jia | Qingjie Ma | Zhaohui Zhu | Fang Li | Xiaona Jing | Shan Liu | A. Yang | Qian-wei Li | Wei-bing Miao | Hao-jie Dai | Zhou-she Zhao
[1] Yang Zhou,et al. 99mTc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin αvβ3 Expression , 2011, Molecular imaging.
[2] Bing Jia,et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Xiaona Jin,et al. Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates , 2011, Molecular Imaging and Biology.
[4] Fan Wang,et al. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature. , 2010, Bioconjugate chemistry.
[5] B. McParland,et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the αv β 3-selective angiogenesis imaging agent 99mtc-nc100692 , 2010, Acta radiologica.
[6] Young-Seung Kim,et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. , 2008, Journal of medicinal chemistry.
[7] A. Hui,et al. The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide 18F-AH111585 in Healthy Volunteers , 2008, Journal of Nuclear Medicine.
[8] Matthias Glaser,et al. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.
[9] W. Oyen,et al. Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[10] A. Cuthbertson,et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. , 2006, Bioorganic & medicinal chemistry letters.
[11] A. Fangberget,et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] Horst Kessler,et al. Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.
[13] M. Schwaiger,et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Horst Kessler,et al. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.
[15] M. Schwaiger,et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] J. Bading,et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. , 2004, Nuclear medicine and biology.
[17] M. Schwaiger,et al. Radiotracer-based strategies to image angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[18] Horst Kessler,et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.
[19] P. Choyke,et al. Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.
[20] W. Oyen,et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. , 2002, Cancer biotherapy & radiopharmaceuticals.
[21] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[22] Li Zhang,et al. Ligand Binding to Integrins* , 2000, The Journal of Biological Chemistry.
[23] Horst Kessler,et al. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .
[24] D. Cheresh,et al. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.
[25] M A Horton,et al. The alpha v beta 3 integrin "vitronectin receptor". , 1997, The international journal of biochemistry & cell biology.
[26] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[27] E Ruoslahti,et al. New perspectives in cell adhesion: RGD and integrins. , 1987, Science.
[28] Richard O. Hynes,et al. Integrins: A family of cell surface receptors , 1987, Cell.